Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.4%

223 terminated/withdrawn out of 2643 trials

Success Rate

90.8%

+4.3% vs industry average

Late-Stage Pipeline

24%

633 trials in Phase 3/4

Results Transparency

53%

1163 of 2203 completed trials have results

Key Signals

89 recruiting1163 with results180 terminated43 withdrawn

Enrollment Performance

Analytics

Phase 1
1098(50.5%)
Phase 3
441(20.3%)
Phase 2
383(17.6%)
Phase 4
192(8.8%)
N/A
57(2.6%)
Early Phase 1
4(0.2%)
2175Total
Phase 1(1098)
Phase 3(441)
Phase 2(383)
Phase 4(192)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2643)

Showing 20 of 2643 trials
NCT06321302Phase 2Active Not Recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Role: lead

NCT07486817Phase 2Recruiting

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Role: lead

NCT05838625Phase 3Completed

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Role: collaborator

NCT04886804Phase 1Active Not Recruiting

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Role: lead

NCT05846230Phase 2Active Not Recruiting

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Role: lead

NCT06632457Phase 3Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Role: lead

NCT07107945Phase 3Recruiting

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Role: lead

NCT06878365Phase 1Active Not Recruiting

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

Role: lead

NCT07553429Phase 1Recruiting

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

Role: lead

NCT06806852Phase 1Active Not Recruiting

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Role: lead

NCT06238622Phase 3Recruiting

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Role: lead

NCT06632444Phase 3Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Role: lead

NCT06745297Phase 1Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated

Role: lead

NCT06077864Phase 3Active Not Recruiting

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Role: lead

NCT06013969Phase 4Active Not Recruiting

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Role: lead

NCT06531824Phase 3Recruiting

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Role: lead

NCT05241275Phase 2Active Not Recruiting

Xenon MRI and Progressive ILD

Role: collaborator

NCT06872892Phase 3Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Role: lead

NCT07306559Phase 1Recruiting

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Role: lead

NCT07036523Phase 2Recruiting

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Role: lead